Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) have been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $49.14.

A number of research analysts have commented on AIMT shares. Cantor Fitzgerald started coverage on Aimmune Therapeutics in a research note on Sunday, December 9th. They set an “overweight” rating and a $23.75 price target on the stock. Credit Suisse Group restated a “buy” rating and set a $40.00 price target on shares of Aimmune Therapeutics in a research note on Tuesday, January 15th. BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. Roth Capital set a $80.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 19th. Finally, Goldman Sachs Group started coverage on Aimmune Therapeutics in a research note on Thursday, December 13th. They set a “neutral” rating and a $32.00 price target on the stock.

NASDAQ:AIMT traded down $0.31 during trading hours on Thursday, reaching $23.34. 544,792 shares of the stock were exchanged, compared to its average volume of 651,935. Aimmune Therapeutics has a twelve month low of $21.22 and a twelve month high of $36.12. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.36 and a beta of -0.11.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Carroll Financial Associates Inc. acquired a new stake in shares of Aimmune Therapeutics in the fourth quarter valued at $28,000. Bank of Montreal Can increased its holdings in Aimmune Therapeutics by 47.9% in the fourth quarter. Bank of Montreal Can now owns 1,516 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 491 shares during the last quarter. Advisor Group Inc. increased its holdings in Aimmune Therapeutics by 84.6% in the fourth quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 796 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Aimmune Therapeutics by 37.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,609 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 708 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in Aimmune Therapeutics in the fourth quarter valued at $96,000. Institutional investors and hedge funds own 77.75% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Consumer Price Index (CPI)

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.